诺和诺德Novo Nordisk（NVO）2025年第三季度财务业绩公告「NYSE」（英文版）（38页）.pdf

1、Financial report for the period 1 January 2025 to 30 September 20255 November 2025Novo Nordisks sales increased by 12%in Danish kroner and by 15%at CER in the first nine months of 2025;R&D pipeline progress continues Operating profit increased by 5%in Danish kroner and 10%at constant exchange rates(

2、CER)to DKK 95.9 billion,impacted by one-off restructuring costs of around DKK 9 billion related to the company-wide transformation with the aimof streamlining Novo Nordisks operations to reinvest for growth.Had Novo Nordisk not incurred such restructuring costsamounting to around DKK 9 billion,opera

3、ting profit would have increased by 15%in Danish kroner and 21%at CER.Sales in US Operations increased by 12%in Danish kroner(15%at CER).Sales in the US were positively impacted by gross-to-net sales adjustments.Sales in International Operations increased by 13%in Danish kroner(16%at CER).Sales with

4、in Diabetes and Obesity care increased by 12%in Danish kroner to DKK 215.7 billion(15%at CER),mainly drivenby Obesity care growth of 37%in Danish kroner to DKK 59.9 billion(41%at CER)and GLP-1 diabetes sales growing 7%inDanish kroner(10%at CER).Rare disease sales increased by 10%in Danish kroner(13%

5、at CER).Within R&D,Novo Nordisk announced that the US FDA had approved an indication for Wegovy for the treatment ofMASH.Further,Novo Nordisk agreed to acquire Akero Therapeutics,Inc.and its phase 3 FGF21 analogue in MASH andOmeros clinical-stage MASP-3 inhibitor zaltenibart within Rare blood disord

6、ers.Also within Rare disease,Novo Nordisksubmitted Mim8 for regulatory approval in the EU and in the US.Finally,cagrilintide phase 3 development was initiated,with the potential to be the first amylin monotherapy treatment on the market for weight management.For the full-year 2025 outlook,sales grow